CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 11 enrolled
Drug / intervention
Continuous Release Dopamine Agonistsdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00465452
NCT00465452Phase 3Completed
CompareCT.gov

The Impact of Switching to Continuous Release Dopamine Agonists on Non-Motor Side Effects

University of Toledo·interventional·Posted Apr 25, 2007·Updated May 16, 2025

In Brief

A Phase 3 clinical trial evaluating Continuous Release Dopamine Agonists for Parkinson Disease. Completed, enrolled 11 participants across 1 site.

Detailed Summary

The purpose of this proposal is to determine if switching PD patients treated with pramipexole to ropinirole CR reduces the non-motor side effects frequently experienced by these patients. Side effects that we will monitor in particular include somnolence, peripheral edema, cognitive decline with and without hallucinations. PD patients followed in the MUO Neurology Clinic who are being treated with pramipexole and have evidence of at least one of the following symptoms: somnolence, cognitive impairment with or without hallucinations, or peripheral edema will be offered the opportunity to participate in this study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 25, 2007
Enrollment StartJan 1, 2007
Primary CompletionMar 1, 2009
Study CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 19.2 years ago

Interventions

Continuous Release Dopamine Agonistsdrug

Continuous Release Dopamine Agonists